Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Weight loss injections, primarily glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound), work through multiple physiological mechanisms to promote weight reduction
Side effects and risks of oral GLP-1s Oral GLP-1s have similar side effects to injectable GLP-1s , with the most common ones being gastrointestinal in nature
DPP-4 inhibitors are body weight neutral and they have demonstrated cardiovascular safety
10.1007/s11103-013-0136-y 101 Magnin-RobertM.AdrianM.TrouvelotS.SpagnoloA.JacquensL.LetouseyP.et al
The NEJM 2023 phase 2 trial enrolled adults with obesity (BMI 30 to 50) without type 2 diabetes and randomized them across multiple retatrutide dose levels versus placebo
US$ 28.13
US$ 27.18
US$ 24.98
US$ 20.97
US$ 26.70
